Vecuronium Requirements According to the Operation Phase During Liver Transplantation Under Desflurane Anesthesia

December 24, 2013 updated by: Gaab Soo Kim, Samsung Medical Center
The vecuronium requirements may be reduced for recipients of living donor liver transplantation, as the vecuronium is eliminated principally by the liver. Furthermore, the requirements may be different according to the phase of surgery. The requirements may also be different according to the preoperative hepatic function as measured by MELD score during prehepatic phase, or graft to recipient body weight ratio (GRWR) during neohepatic phase. Therefore, the investigators are trying to investigate the difference of vecuronium requirements according to the phase of surgery or MELD score, GRWR.

Study Overview

Status

Completed

Conditions

Detailed Description

The vecuronium requirements may be reduced for recipients of living donor liver transplantation, as the vecuronium is eliminated principally by the liver. Furthermore, the requirements may be different according to the phase of surgery. The requirements may by further reduced during anhepatic phase of liver transplantation. And the requirements may be increased as the graft functions during neohepatic phase.

We also postulated that the requirements may be different according to the preoperative hepatic function during preanhepatic phase, and according to the graft to recipient body weight ratio (GRWR) during neohepatic phase.

Therefore, we are trying to investigate the difference of vecuronium requirements according to the phase of surgery, MELD score, GRWR.

Study Type

Observational

Enrollment (Actual)

35

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

20 years to 69 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Patients undergoing elective living donor liver transplantation

Description

Inclusion Criteria:

  • patients undergoing elective living donor liver transplantation

Exclusion Criteria:

  • patients who can not undergo train-of-four test due to central or peripheral neuromuscular disease.
  • patients with severe cardiopulmonary diseases.
  • patients who received transfusion with more than 10 units of packed red blood cells.
  • primary non-functioning graft immediately after reperfusion of the graft.
  • patients who administered drugs that influences the metabolism of vecuronium (such as anticonvulsant: phenytoin, carbamazepine, primidone, sodium valproate)
  • patients undergoing cadaver donor liver transplantation

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Time Perspectives: Prospective

Cohorts and Interventions

Group / Cohort
High MELD group
Preoperative MELD score greater than 20
Low MELD group
Preoperative MELD score lesser than 20

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
vecuronium requirements during preanhepatic phase
Time Frame: during prehepatic phase of liver transplantation
total vecuronium requirements as guided by Train-of-four neuromuscular monitoring during preanhepatic phase
during prehepatic phase of liver transplantation
vecuronium requirements during anhepatic phase
Time Frame: during anhepatic phase of liver transplantation
total vecuronium requirements as guided by Train-of-four neuromuscular monitoring during anhepatic phase
during anhepatic phase of liver transplantation
vecuronium requirements during neohepatic phase
Time Frame: during neohepatic phase of liver transplantation
total vecuronium requirements as guided by Train-of-four neuromuscular monitoring during neohepatic phase
during neohepatic phase of liver transplantation

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Samsung Medical Center

Investigators

  • Study Director: Gaab Soo Kim, M.D.,Ph.D., Samsung Medical Center

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

June 1, 2011

Primary Completion (Actual)

December 1, 2011

Study Completion (Actual)

December 1, 2011

Study Registration Dates

First Submitted

June 21, 2011

First Submitted That Met QC Criteria

June 22, 2011

First Posted (Estimate)

June 23, 2011

Study Record Updates

Last Update Posted (Estimate)

December 25, 2013

Last Update Submitted That Met QC Criteria

December 24, 2013

Last Verified

December 1, 2013

More Information

Terms related to this study

Keywords

Other Study ID Numbers

  • 2011-04-015

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Liver Transplantation

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Uzbekistan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe